Engineering Antibodies for the Treatment of Infectious Diseases

Historically, serum therapy was previously used to combat infectious pathogens. However, serum sickness and anaphylaxis limited its broad application. The advancement of antibody engineering technologies has made it feasible to generate monoclonal antibodies. There are divergent methods for antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Gaowei, Li, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121079/
https://www.ncbi.nlm.nih.gov/pubmed/29549641
http://dx.doi.org/10.1007/978-3-319-72077-7_10
_version_ 1783515120508338176
author Fan, Gaowei
Li, Jinming
author_facet Fan, Gaowei
Li, Jinming
author_sort Fan, Gaowei
collection PubMed
description Historically, serum therapy was previously used to combat infectious pathogens. However, serum sickness and anaphylaxis limited its broad application. The advancement of antibody engineering technologies has made it feasible to generate monoclonal antibodies. There are divergent methods for antibody engineering and optimization. In this chapter, we summarized the latest developments in engineering antibodies for infectious diseases.
format Online
Article
Text
id pubmed-7121079
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-71210792020-04-06 Engineering Antibodies for the Treatment of Infectious Diseases Fan, Gaowei Li, Jinming Recombinant Antibodies for Infectious Diseases Article Historically, serum therapy was previously used to combat infectious pathogens. However, serum sickness and anaphylaxis limited its broad application. The advancement of antibody engineering technologies has made it feasible to generate monoclonal antibodies. There are divergent methods for antibody engineering and optimization. In this chapter, we summarized the latest developments in engineering antibodies for infectious diseases. 2018-03-17 /pmc/articles/PMC7121079/ /pubmed/29549641 http://dx.doi.org/10.1007/978-3-319-72077-7_10 Text en © Springer International Publishing AG, part of Springer Nature 2017 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Fan, Gaowei
Li, Jinming
Engineering Antibodies for the Treatment of Infectious Diseases
title Engineering Antibodies for the Treatment of Infectious Diseases
title_full Engineering Antibodies for the Treatment of Infectious Diseases
title_fullStr Engineering Antibodies for the Treatment of Infectious Diseases
title_full_unstemmed Engineering Antibodies for the Treatment of Infectious Diseases
title_short Engineering Antibodies for the Treatment of Infectious Diseases
title_sort engineering antibodies for the treatment of infectious diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121079/
https://www.ncbi.nlm.nih.gov/pubmed/29549641
http://dx.doi.org/10.1007/978-3-319-72077-7_10
work_keys_str_mv AT fangaowei engineeringantibodiesforthetreatmentofinfectiousdiseases
AT lijinming engineeringantibodiesforthetreatmentofinfectiousdiseases

Ejemplares similares